Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients
Clinical Utility of Fluoroestradiol F18 PET/CT in Metastatic Breast Cancer Patients With ER-Positive and HER2-Negative Primary Lesions After Progression on First Line Hormonal Therapy
Sponsor: GE Healthcare
Terminated
Sponsor discretion (low recruitment rate)
Other terminated trials from GE Healthcare
Other Metastatic Breast Cancer trials with similar outcome
A observational or N/A phase clinical study on Metastatic Breast Cancer, this trial is terminated or withdrawn. The trial is conducted by GE Healthcare and has accumulated 16 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
16 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Aug 2024 — Sep 2024 [monthly]
Terminated
-
Jul 2024 — Aug 2024 [monthly]
Terminated
Status: Recruiting → Terminated
-
Feb 2024 — Jul 2024 [monthly]
Recruiting
-
Nov 2023 — Feb 2024 [monthly]
Recruiting
▶ Show 11 earlier versions
-
Jul 2023 — Nov 2023 [monthly]
Recruiting
-
Jun 2023 — Jul 2023 [monthly]
Recruiting
-
Apr 2023 — Jun 2023 [monthly]
Recruiting
-
Feb 2023 — Apr 2023 [monthly]
Recruiting
-
Jan 2023 — Feb 2023 [monthly]
Recruiting
-
Nov 2022 — Jan 2023 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Oct 2022 — Nov 2022 [monthly]
Not Yet Recruiting
-
Sep 2022 — Oct 2022 [monthly]
Not Yet Recruiting
-
Feb 2022 — Sep 2022 [monthly]
Not Yet Recruiting
-
Dec 2021 — Feb 2022 [monthly]
Not Yet Recruiting
-
Nov 2021 — Dec 2021 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- GE Healthcare
- Medpace, Inc.
- Simbec-Orion Group
- Zionexa
For direct contact, visit the study record on ClinicalTrials.gov .